A new study suggests Paxlovid may not reduce risk of covid hospitalizations and all-cause deaths in vaccinated adults ages 65 to 74. Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests.
Paxlovid — Pfizer’s combination of nirmatrelvir and ritonavir — has been found to reduce symptoms, hospitalizations and deaths in unvaccinated, at-risk patients. However, a Pfizer trial published in 2024 found the medication didn’t significantly shorten the duration of symptoms in vaccinated adults.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.